ALT
Live chart
What they do
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
For information only · Important disclosures
Grades vs sector
No sector grades for ALT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2025-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Quality & financial health
Piotroski F-score 4/9 · last two fiscal years
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $41.0K | $-88.1M | $-67.5M |
| 2024 | $20.0K | $-95.1M | $-79.8M |
| 2023 | $426.0K | $-88.4M | $-75.9M |
| 2022 | $-68.0K | $-84.7M | $-62.7M |
| 2021 | $4.4M | $-97.1M | $-90.4M |
| 2020 | $8.2M | $-49.0M | $-34.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | -0.12 | -0.12 | +4.0% |
| 2026-05-13 | -0.25 | -0.18 | +28.0% |
| 2026-03-05 | -0.24 | -0.27 | -11.2% |
| 2025-11-06 | -0.27 | -0.21 | +21.0% |
| 2025-08-12 | -0.32 | -0.27 | +15.8% |
| 2025-05-13 | -0.34 | -0.26 | +23.9% |
| 2025-02-27 | -0.34 | -0.33 | +1.5% |
| 2024-11-12 | -0.36 | -0.32 | +10.5% |
Insider trades
$44.2K
–
–
–
–
–
–
Stats refreshed 2026-10-21 18:00:13 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026